Back to Search Start Over

Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU.

Authors :
Ali F
Wijdicks EF
Source :
Neurocritical care [Neurocrit Care] 2020 Feb; Vol. 32 (1), pp. 286-294.
Publication Year :
2020

Abstract

Immune response against neuronal and glial cell surface and cytosolic antigens is an important cause of encephalitis. It may be triggered by activation of the immune system in response to an infection (para-infectious), cancer (paraneoplastic), or due to a patient's tendency toward autoimmunity. Antibodies directed toward neuronal cell surface antigens are directly pathogenic, whereas antibodies with intracellular targets may become pathogenic if the antigen is transiently exposed to the cell surface or via activation of cytotoxic T cells. Immune-mediated encephalitis is well recognized and may require intensive care due to status epilepticus, need for invasive ventilation, or dysautonomia. Patients with immune-mediated encephalitis may become critically ill and display clinically complex and challenging to treat movement disorders in over 80% of the cases (Zhang et al. in Neurocrit Care 29(2):264-272, 2018). Treatment options include immunotherapy and symptomatic agents affecting dopamine or acetylcholine neurotransmission. There has been no prior published guidance for management of these movement disorders for the intensivist. Herein, we discuss the immune-mediated encephalitis most likely to cause critical illness, clinical features and mechanisms of movement disorders and propose a management algorithm.

Subjects

Subjects :
Adrenergic alpha-Antagonists therapeutic use
Adrenergic beta-Antagonists therapeutic use
Analgesics, Opioid therapeutic use
Anticonvulsants therapeutic use
Antiparkinson Agents therapeutic use
Autoantibodies immunology
Autoimmune Diseases of the Nervous System complications
Autoimmune Diseases of the Nervous System immunology
Autoimmune Diseases of the Nervous System physiopathology
Benzodiazepines therapeutic use
Catatonia drug therapy
Catatonia etiology
Catatonia physiopathology
Chorea drug therapy
Chorea etiology
Chorea physiopathology
Critical Illness
Dopamine Antagonists therapeutic use
Dyskinesias drug therapy
Dyskinesias etiology
Dyskinesias physiopathology
Dystonia drug therapy
Dystonia etiology
Dystonia physiopathology
Emergencies
Encephalitis complications
Encephalitis immunology
Encephalitis physiopathology
Humans
Hypnotics and Sedatives therapeutic use
Immunoglobulins, Intravenous therapeutic use
Immunologic Factors therapeutic use
Intensive Care Units
Movement Disorders etiology
Movement Disorders physiopathology
Myoclonus drug therapy
Myoclonus etiology
Myoclonus physiopathology
Paraneoplastic Syndromes, Nervous System complications
Paraneoplastic Syndromes, Nervous System drug therapy
Paraneoplastic Syndromes, Nervous System immunology
Paraneoplastic Syndromes, Nervous System physiopathology
Plasmapheresis
Adrenal Cortex Hormones therapeutic use
Autoimmune Diseases of the Nervous System drug therapy
Cholinergic Antagonists therapeutic use
Dopamine Agents therapeutic use
Encephalitis drug therapy
Immunosuppressive Agents therapeutic use
Movement Disorders drug therapy
Neuromuscular Blocking Agents therapeutic use

Details

Language :
English
ISSN :
1556-0961
Volume :
32
Issue :
1
Database :
MEDLINE
Journal :
Neurocritical care
Publication Type :
Academic Journal
Accession number :
31732848
Full Text :
https://doi.org/10.1007/s12028-019-00875-5